Pharmacodynamics and pharmacokinetics of bicalutamide: Defining an active dosing regimen

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 26-28

  Denis, Louis ^a   Mahler, C ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MASTALGIA; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0029560859     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80004-5     Document Type: Article

References (11)

1. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterton G, and Tucker H: ICI 176, 334: A novel nonsteroidal, peripherally selective antiandrogen. J Endocrinol 113: R7-R9, 1987.
2. Denis L: A new nonsteroidal antiandrogen, in Murphy GP and Khoury S (Eds): Therapeutic Progress in Urological Cancers. New York, Alan Liss, 1989, pp 95-104.
3. Verhelst J, Denis L, Van Vliet P, et al: Endocrine profiles during administration of the new nonsteroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol 41: 525-530, 1994.
4. Furr BJA: Casodex: Preclinical studies. Eur Urol 18: 2-9, 1990.
5. Eri LM, and Urdal P: Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Eur Urol 27: 274-279, 1995.
6. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, and Denis L: The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 18: 10-17, 1990.
7. Cockshott ID, Sotaniemi EA, Cooper KJ, and Jones DC : The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharm 36: 339-343, 1993.
8. Tyrell CJ, Denis L, Newling D, Soloway M, Channer K, and Cockshott ID: Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer: an overview of the efficacy, tolerability and pharmacokinetics from three dose-ranging studies. Eur Urol (submitted for publication).
9. McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, and Yates RA: Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 23: 1241-1253, 1993.
10. Waymont B, Blackledge GRP, Tyrell CJ, Robinson MRG, and Williams JL: Efficacy and safety of the non-steroidal antiandrogen Casodex in early clinical trials for advanced prostate cancer. Br J Cancer 62: 499, 1990.
11. Blackledge GRP: Clinical aspects of Casodex, in Denis L (Ed): Anti-Androgens in Prostatic Diseases. Heidelberg, Springer Verlag (in print).